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ses revealed that the time needed to complete in vivo toxicolog-
ical evaluations of all NMs existing by 2009 would take at least 
three to five decades (Choi et al., 2009). Consequently, there is 
demand for robust and regulatory relevant strategies to prioritize 
and/or to reduce animal testing. 
Global efforts are being made to implement the 3Rs (replace-
ment, reduction and refinement) concept (European Commis-
sion, 2020) that seeks for alternative animal-free testing method-
ologies (Collins et al., 2017; Ostermann et al., 2020). However, 
many in vitro approaches for NM toxicity evaluation are compli-
cated due to the unique nano-specific properties that may induce 
different interferences with the test system and thus require ei-
ther adaptation of existing or development of new methods less 
1  Introduction
Manufactured nanomaterials (NMs) are increasingly used in 
a wide range of industrial applications, and novel NM-enabled 
products are routinely introduced into the market (Vance et al., 
2015; Stark et al., 2015). The constant increase in production 
and use of NMs is raising concerns among different stakeholder 
groups, including consumers, regulatory authorities, and policy 
makers, regarding the effects of NMs on human and environmen-
tal health. Decades of nanotoxicological research have revealed 
that the small size and enhanced surface reactivity of NMs may 
induce adverse effects at both cellular and whole organism lev-
el (Shi et al., 2013; Murugadoss et al., 2017). However, analy-
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Abstract
Manufactured nanomaterials (NMs) are increasingly used in a wide range of industrial applications leading to a constant 
increase in the market size of nano-enabled products. The increased production and use of NMs are raising concerns 
among different stakeholder groups with regard to their effects on human and environmental health. Currently, nanosafety 
hazard assessment is still widely performed using in vivo (animal) models, however the development of robust and reg-
ulatory relevant strategies is required to prioritize and/or reduce animal testing. An adverse outcome pathway (AOP) is 
a structured representation of biological events that start from a molecular initiating event (MIE) leading to an adverse 
outcome (AO) through a series of key events (KEs). The AOP framework offers great advancement to risk assessment and 
regulatory safety assessments. While AOPs for chemicals have been more frequently reported, the AOP collection for 
NMs is limited. By using existing AOPs, we aimed to generate simple and testable strategies to predict if a given NM has 
the potential to induce a MIE leading to an AO through a series of KEs. Firstly, we identified potential MIEs or initial KEs 
reported for NMs in the literature. Then, we searched the identified MIE or initial KEs as keywords in the AOP-Wiki to find 
associated AOPs. Finally, using two case studies, we demonstrate how in vitro strategies can be used to test the identified 
MIE/KEs.
This is an Open Access article distributed under the terms of the Creative Commons 
Attribution 4.0 International license (http://creativecommons.org/licenses/by/4.0/), 
which permits unrestricted use, distribution and reproduction in any medium, provi-
ded the original work is appropriately cited. 
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started by the OECD Working Party on Manufactured Nanoma-
terials (WPMN) to support the development of future AOPs for 
NM RA and categorization. The AOP framework offers great ad-
vancement to RA and human hazard assessments of NMs, which 
often diverge from classical dose-response relationships and ex-
hibit particulate-specific toxicity. Indeed, even small changes in 
their physico-chemical properties may significantly impair the 
nano-bio interface, aggravating predictability of traditional RA 
tools and methods. 
It has been discussed that existing AOPs for chemicals can po-
tentially be used for NMs as these may share similar KEs with 
chemicals (Ede et al., 2020). The AOP provides the mecha-
nistic representation of an AO initiated by a MIE, thus reflect-
ing the molecular level, and making possible the connection 
with the NM’s physico-chemical properties via in silico tools, 
such as quantitative analyses of structure-activity relationships 
(QSARs).
While extensive efforts have been made towards the devel-
opment of AOPs for chemicals, AOPs specific to NMs are still 
scarce. At the end of 2020, the OECD WPMN, as part of the Na-
noAOP project, reported a methodology to identify, analyze and 
evaluate existing scientific data to prioritize NM-relevant KEs 
and so to contribute to the development of a knowledge base 
to inform AOP development and assessment for NMs (OECD, 
2020). One of the main outcomes of this project was the devel-
opment of a case study on the inflammation pathway and analy-
sis of a specific KE for this pathway to establish an approach to 
advance future NM-related AOPs (OECD, 2020). Gerloff et al. 
(2017) in his study attempted to merge existing chemically in-
duced liver fibrosis AOPs and proposed a putative AOP for metal 
oxide NMs by combining in vivo and in vitro literature data ob-
tained for TiO2 and SiO2 NMs. However, the potential applica-
tion of chemical AOPs to NMs is not comprehensively explored. 
prone to biased results (Ostermann et al., 2020). Moreover, even 
small variabilities in the physico-chemical properties of NMs 
have been shown to influence the toxicological outcome, which 
further challenges the grouping and read-across analysis of NMs. 
The development of intelligent and more efficient methodologies 
with lower costs is therefore urgently needed for hazard and risk 
assessment (RA) of NMs. 
The adverse outcome pathway (AOP) framework can signifi-
cantly support the advancement of RA approaches by developing 
predictive methods that utilize mechanistic and evidence-based 
data. The AOPs, first described a decade ago (Ankley et al., 
2010), refer to conceptual structures portraying biological fail-
ures initiated by the interaction of a chemical with a biomolecule 
or biosystem that can perturb normal biology, impairing critical 
function and leading to adverse outcome(s) (AO) at organism or 
population level. 
As shown in Figure 1, AOP comprise a series of key events 
(KEs) along a biological pathway from the molecular initiating 
event (MIE) to the AO. As such, the AOP framework provides 
systematic knowledge about key toxic mechanisms, thus being 
very effective at characterizing the individual biological impact 
and toxicological potential of substances and significantly im-
proving the prediction of adverse effects. 
Worldwide, there are many initiatives for further development 
and advancement of the AOP framework; at European level, the 
OECD has made significant efforts in this direction and initiated 
an AOP Development Programme in 2012. In collaboration with 
the U.S. EPA and the U.S. Army Engineer Research and Devel-
opment Center, the EC’s Joint Research Centre launched in 2014 
the AOP Knowledge Base (AOP-KB) as a web-based tool en-
compassing the e.AOP.Portal, the AOP-Wiki, Effectopedia, the 
AOP Xplorer, and the Intermediate Effects Database (Delrue et 
al., 2016). In 2016, the NanoAOP project (OECD, 2020) was 
Fig. 1: A schematic representation of the adverse outcome pathway (AOP) framework (inspired by Sachana et al., 2018) 
An AOP is triggered by a molecular initiating event (MIE), an initial interaction with a biological target (Anchor 1), which leads  
to a sequential cascade of cellular, tissue and organ responses (key events), linked to each other by key-event relationships (KER)  
to result in an adverse outcome (AO) of regulatory relevance.
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Thus, we aimed to generate simple and testable strategies for 
the development of AOPs for NMs that are of relevance for hu-
man health. Our approach is based on using existing AOPs to pre-
dict if a given NM has the potential to induce a MIE leading to 
an AO through a series of KEs. Firstly, we identified potential 
MIEs reported for NMs in the literature. Then, we searched in the 
AOP-Wiki using the identified MIEs (as keywords) to find associ-
ated AOPs that can be applied to NMs and can be verified using in 
vitro and in silico approaches through testing the involved KEs.       
2  Methodology
The first step towards generating testable AOPs for NMs was 
a literature search using the following scientific databases: 
PubMed, Embase, Scopus and Web of Science. The search, 
performed in the period until 1/12/2020 using the key words 
“adverse outcome pathway” OR “AOP” AND “nano*”, re-
sulted in 960 papers in total. After careful analysis and refine-
ment on duplicates, reviews, AOPs/AOs reports, and type of 
organisms studied therein, 32 papers that covered both in vitro 
and in vivo studies on mammals were selected for further anal-
ysis. Next, each of the selected papers was evaluated by the 
software-based tool ToxRTool (European Commission, 2013), 
which assesses the reliability of in vivo or in vitro human tox-
icity studies. According to the criteria described by (Klimisch 
et al., 1997), this evaluation revealed that only 15% of select-
ed papers provided reliable data with some restrictions, i.e., da-
ta are potentially useful but their relevance should be checked 
for intended purpose. The rest of the papers (85%) were eval-
uated as providing reliable data without restrictions. The pa-
pers then underwent data extraction, which included the iden-
tification of NM-induced AOs and MIEs relevant for NMs. In 
this study, we focused on the identification of initiating events 
relevant for NMs because chemicals may share common KEs 
with NMs, but major differences lie in their way of interaction 
with biological targets. To achieve this, the AOs and the respec-
tive first event (mainly molecular/cellular level key event) re-
ported in each study were summarized. When analyzing these 
data, we found that certain events were consistently reported. 
Finally, the identified initiating events were used to search the 
AOP-Wiki for potential AOPs applicable for NMs, and all the 
AOPs linked to each of the used keywords were summarized. 
Since inhalation and ingestion are the primary routes of NM 
exposure, we focused on lung and liver fibrosis to describe our 
strategy to generate testable AOPs. 
3  Results
3.1  Identification of (molecular) initiating events  
relevant for NMs
To identify potential MIEs relevant for NMs, AOs reported in 
each of the selected research papers and their respective report-
ed/identified first event were consolidated as presented in Table 
1. The KEs can be described as a measurable change in the bio-
logical state representing an essential event for further biological 
effect(s) and progression towards the AO, but not bridging levels 
of biological organization. The critical step in AOP development 
is the identification of a MIE that is defined as “the initial inter-
action between a molecule and a biomolecule or biosystem that 
can be causally linked to an outcome via a pathway” (Villeneuve 
et al., 2014). In this definition, “a molecule” can be replaced by a 
NM, but the chemistry of the MIE should be carefully described 
to provide a coherent link between the physico-chemical proper-
ties of NMs and MIEs that is stronger than the links to adverse 
endpoints (Allen et al., 2014). When analyzing the extracted da-
ta from papers (Tab. 1), five potential MIEs for NMs were iden-
tified: (i) Interaction of particles/fibers with cell membranes/
biomolecules, (ii) reactive oxygen species (ROS) formation/
generation, (iii) lysosomal injury/damage/disruption, (iv) DNA 
damage/methylation, and (v) inflammation induction. All these 
initial KEs were obtained from both in vitro and in vivo studies. 
Instead of MIE, the term “initial key event (initial KE)” is used in 
subsequent sections because not all identified events occur at the 
molecular level.
Tab. 1: Summary of AO and their respective (M)IE
Reference Types of particles used Adverse outcomes (AO) Models First event reported in the study
Ndika Single-walled (SWCNTs) and multi- Cell death and DNA in vitro	 Interaction	of	fibers	with	cell 
et al., 2018 walled carbon nanotubes (MWCNTs) repair impairment  membranes
Barosova	 MWCNTs	and	silica	quartz	particles	 Lung	fibrosis	 in vitro	 Interaction	of	particles/fibers	with	cell 
et al., 2020    membranes
Bezerra SWCNTs, TiO2 nanoparticles (NPs)  Skin sensitization in vitro Interaction of particles with skin 
et al., 2021 and fullerenes   proteins
Zhang, H.  Rare earth oxide, ZnO, Ag, TiO2 and Compromised  in vitro Interaction of particles with  
et al., 2018 iron oxide NPs phagocytosis  biomolecules/membrane
Nikota	 MWCNTs	 Lung	fibrosis	 in vivo		 Interaction	of	fibers	with	cell 
et al., 2017    membranes
Huaux MWCNTs Mesothelioma in vivo	 Interaction	of	fibers	with	cell 
et al., 2016    membranes
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Reference Types of particles used Adverse outcomes (AO) Models First event reported in the study
Labib	 MWCNTs	 Lung	fibrosis	 in vivo	 Interaction	of	fibers	with	cell 
et al., 2016    membranes 
Shvedova	 MWCNTs	 Pulmonary	inflammation	 in vivo		 Interaction	of	fibers	with	cell 
et	al.,	2016	 	 and	fibrosis		 	 membranes
Nikota	 MWCNTs	 Lung	fibrosis	 in vivo		 Interaction	of	fibers	with	cell 
et al., 2016    membranes
Pavan and Crystalline silica Persistent lung  in vitro and Interaction of particles with cell 
Fubini,	2017	 	 inflammation	 in vivo membranes and membranolysis
Dekkers Ag, ZnO and CeO2 NPs  Death and cancer in vitro ROS formation 
et al., 2018  progression  
Garcia- PVP-coated Ag NPs Liver and brain damage in vitro  ROS formation and dopamine receptor 
Reyero    antagonism 
et al., 2014
Boyles CuO NPs Apoptosis in vitro ROS formation and accumulation of  
et al., 2016    amino acid and glycerophosphocholine
Pisani Fumed silica NPs Cell death  in vitro ROS formation 
et al., 2015
Duan Silica, Fe3O4 and CoO nanoparticles Apoptosis in vitro ROS formation 
et al., 2016
Yang Cu NPs Weight loss in vivo  ROS formation 
et al., 2010
Lei Cu NPs Liver and kidney damage in vivo  MDA formation and mitochondrial 
et al., 2015    dysfunction
Hansjosten CeO2, ZnO, TiO2, Ag and silica NPs Cell death in vitro	 Lysosomal	acidification 
et al., 2018
Wang	 SWCNTS,	graphene	and	graphene	 Lung	fibrosis	 in vivo and  Lysosome injury 
et al., 2015 oxide  in vitro 
Wang SWCNTs Collagen deposition  in vitro and Lysosome injury 
et al., 2018   in vivo 
Bourdon	 Carbon	black	NPs	 Lung	fibrosis	 in vitro DNA damage 
et al., 2013
Chen Ag, Au, TiO2, ZnO, CNTs and Impaired cytoskeleton in vitro  DNA methylation 
et al., 2017 graphene oxide   
Scala et 10 different types of carbon NPs Cancer in vitro DNA methylation 
al., 2018
Gomes Coated and uncoated Ag NPs Decreased reproduction  in vivo DNA damage, apoptosis stimulation 
et al., 2017  and increased mortality  and ROS formation
Pisani Magnetic (core-FE2O3) mesoporous Cholestatic liver injury in vitro	 Induction	of	IL-1	and	TNFα/BSEP-	 
et al., 2017 silica nanocarriers   inhibition
Ma	 Coated	and	uncoated	MWCNTs	 Systemic	inflammation	 in vivo  Induction of IL-6 
et al., 2017  and anemia 
Aragon MWCNTs Systemic (neuro)  in vivo	 Inflammation	in	the	lung 
et	al.,	2017	 	 inflammation	
Ma Carboxylated MWCNTs Arthritis in vivo	and		 Induction	of	IL-1β	and	TNF-α 
et al., 2016   in vitro in vitro	or	TNF-α	and	IL-6	in vivo
Poon TiO2, ZnO and Ag NPs Immune system in vitro Activation of intracellular pattern 
et al., 2017  dysregulation  recognition receptors
Thai TiO2 and CeO2 NPs Liver and lung damage in vitro Altered signaling pathways associated  
et al., 2019    with cytotoxicity
Hao ZnO NPs Systemic shortage of in vivo  Altered expression of lipid synthesis of 
et al., 2017  lipid or hepatic steatosis  liver growth factors and apoptotic genes
Zhang, J.  Gadolinium and manganese Kidney damage in vivo Interruption of calcium homeostasis 
et al., 2018 oxide NPs
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tial of an NM to induce an initiating KE leading to AO through 
causally linked KEs. Our final goal is to generate AOPs that can 
be tested using in vitro/in silico tools in compliance with the 3Rs 
principle.
3.3.1  Case study 1: Lung fibrosis
AOP 173 (Fig. 3; substance interaction with lung epithelial and 
macrophage cell membrane leading to lung fibrosis) has been the 
most discussed AOP for its potential application to NMs. Briefly, 
the interaction between the substance and components of the cel-
lular membrane (MIE) leads to the release of pro-inflammatory 
mediators (KE1) that promote the recruitment of pro-inflammato-
ry cells into the lungs (KE2). Persistent inflammation leads to the 
loss of alveolar capillary membrane integrity (KE3) and activa-
tion of the adaptive immune response (T helper type 2 activation) 
(KE4), during which anti-inflammatory and pro-repair/fibrotic 
molecules are secreted. The repair and healing process stimulates 
fibroblast proliferation and myofibroblast differentiation (KE5), 
leading to synthesis and deposition of an extracellular matrix or 
collagen (KE6), and eventually lung fibrosis (AO). It appeared 
that some of the components of this AOP cannot be replaced with 
in vitro cellular assays (such as KE2, KE3 and KE4). 
NMs, particularly carbon nanotubes (CNTs), were shown to 
induce lung fibrosis in vivo via different interactions and path-
ways. When mining the literature, we found a recent comprehen-
sive pathway analysis of in vitro results relating to multi-walled 
(MW) CNT-induced lung fibrosis (Vietti et al., 2016). Based on 
this information, we propose an AOP consisting of the major KEs 
that can be tested/verified under in vitro settings. Figure 4 shows 
the aligned initial KE-KEs-AO pattern that can be measured in 
vitro to predict the lung fibrotic responses in vivo and different 
strategies to test the potential of a given NM to induce an AO re-
3.2  Identification of potential AOPs in the AOP-Wiki 
The AOP-Wiki “Key Events” module of the freely accessible 
web-based AOP-KB was used to identify AOPs applicable for 
NMs. The search revealed several titles linked to initial KEs 
identified in the first step (Tab. 1), e.g., the results for “Interac-
tion of particles with cell membranes” as depicted in Figure 2. 
Then, the AOPs linked to each of these titles were retrieved: Ta-
ble 2 shows the potential AOPs found in the AOP-Wiki linked to 
each of these initial KEs. We did not use the term “inflammation” 
in the search as it was widely recognized as a KE rather than an 
initiating event (Halappanavar et al., 2019). A detailed analysis 
of titles linked to different keyword searches and identification of 
associated AOPs is provided in File S11. 
3.3  Generation of testable strategies using simple  
in vitro/in silico experiments
In this work, initial KEs are considered as one critical component 
that can be shared by more than one pathway. The sequence of 
intermediate KEs connecting the initial KE with AOs should be 
described, including the definition of the biological state, meth-
ods used for intermediate KE observation and measurement, as 
well as evaluation of taxonomic applicability of a particular KE 
(Villeneuve et al., 2014). Another important AOP component is 
the KE relationship (KER) that is supported by empirical evi-
dence and establishes directed and quantitative relationships be-
tween KEs. Weight of evidence for KER can be obtained by liter-
ature search (as in our case), targeted experiments, data mining, 
or modelling approaches. Finally, the utilization of a particular 
AOP within AOP-KB as the basis for an AOP network relies on a 
simple AOP description. It is important to mention here that our 
main objective was to extract and integrate relevant information 
from the literature/database to build a strategy to test the poten-
1 doi:10.14573/altex.2102191s1
Fig. 2: Screenshot of AOP-Wiki page during the search for potential AOPs using “Interaction of particles with cell membranes” 
in “key event” search tab
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Tab. 2: Summary of AOPs associated with NM-relevant initial KEs identified from the literature search 
Different keywords for each initial KE were used to retrieve all AOPs from the AOP-Wiki that can be explored for NMs.
Key word search Associated AOPs AOP number
Interaction of Substance interaction with the lung cell membrane leading to lung fibrosis 173
particles/fibers	with Ionizing energy leading to lung cancer 272
cell membranes,  Lysosomal uptake induced liver fibrosis 144
Interaction of
 Mitochondrial complex inhibition leading to liver injury 273
particles/fibers	with
 Lung surfactant function inhibition leading to immediate adverse lung effects 302biomolecules
 ACE2 binding to viral S protein, acute respiratory distress 320
 Mitochondrial dysfunction and neurotoxicity 3
 Chemical binding to tubulin in oocytes leading to aneuploid offspring 106
 Complex I inhibition leads to Fanconi syndrome 276
 Receptor mediated endocytosis and lysosomal overload leading to kidney toxicity 257
 Ionotropic glutamatergic receptors and cognition 48
Lysosomal damage, Substance interaction with the lung cell membrane leading to lung fibrosis 173
lysosomal disruption,  Lysosomal uptake induced liver fibrosis 144
lysosomal injury Protein alkylation to liver fibrosis 38
 IKK complex inhibition leading to liver injury 278
 Mitochondrial complex inhibition leading to liver injury 273
 Increased DNA damage leading to breast cancer 293
 RONS leading to breast cancer 294
 Oxidative stress and developmental impairment in learning and memory 17
 Receptor mediated endocytosis and lysosomal overload leading to kidney toxicity 257
 Mitochondrial dysfunction and neurotoxicity 3
 ionotropic glutamatergic receptors and cognition 48
 Binding of antagonist to NMDARs impairs cognition 13
 Binding of antagonist to NMDARs can lead to neuroinflammation and neurodegeneration 12
 AChE inhibition leading to neurodegeneration 281
DNA damage,  Oxidative DNA damage, chromosomal aberrations and mutations 296
oxidative DNA ER activation to breast cancer 200
damage, DNA strand Increased DNA damage leading to breast cancer 293
breaks, DNA
 RONS leading to breast cancer 294
methylation
 Excessive ROS leading to mortality  330
 Frustrated phagocytosis-induced lung cancer 303
 Ionizing energy leading to lung cancer 272
 ROS production leading to population decline via follicular atresia 216
 Uncoupling of OXPHOS leading to growth inhibition  266
 Thermal stress leading to population decline  325
 NADPH oxidase activation leading to reproductive failure 207
 Alkylation of DNA leading to reduced sperm count 322
 DNMT inhibition leading to population decline (1) 336
 DNMT inhibition leading to population decline (2) 337
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oli. The NM interaction with epithelial cells (bronchial or alveo-
lar) could lead to NLRP3 (NOD-like receptor family, LRR- and 
pyrin domain containing 3) inflammasome activation either by 
lysosomal injury (can be measured by assays such as acridine or-
ange or neutral red uptake) or membrane perturbation (can be as-
sessed by measuring lactate dehydrogenase (LDH) release) and 
promote pro-inflammatory and pro-fibrotic mediator release such 
as IL-1β and IL-18. Caspase-1 activation is an essential compo-
nent of inflammasome activation and processing of IL-1β and IL-
18. Therefore, caspase-1 activity can be measured as an indicator 
of inflammasome activation (KE1). Subsequent IL-1β and IL-18 
release can be measured by ELISA in the medium of the cell cul-
tures to quantify pro-inflammatory and pro-fibrotic mediator re-
lease (KE2). 
As secreted cytokines may act along different pathways (see 
Fig. 4), we propose three test strategies (TS): 
TS1: IL-1β promotes the secretion of TGF-β1, which plays a 
key role in the epithelial-mesenchymal transition (EMT) (KE3). 
lated to lung fibrosis. In this in vitro testable AOP, we propose 
KE6 of AOP 173 (ECM deposition, see Fig. 3) as the AO.
Frustrated phagocytosis and lysosomal injury of MWCNTs are 
the key determinants of lung fibrosis initiating events (Vietti et 
al., 2016). When mining the literature, we have also found that 
high aspect ratio nanomaterials such as nanowires, nanorods and 
other NMs such as fumed silica and cerium oxide also induce in-
flammasome activation via lysosomal injury, membrane pertur-
bation and/or frustrated phagocytosis (Wang et al., 2017). De-
spite the lack of information that inflammasome activation in-
duced by these NMs potentially can lead to lung fibrosis, the 
downstream biological processes of the inflammasome activa-
tion induced by different NMs could be similar to that induced by 
MWCNTs. Therefore, we use the existing information specific 
for MWCNTs and propose the following strategy to test the po-
tential of NMs to induce an AO related to lung fibrosis.
Epithelial cells are the first cells to encounter NMs once they 
reach the deeper parts of the lung such as bronchioles and alve-
 DNMT inhibition leading to transgenerational effects (1) 340
 DNMT inhibition leading to transgenerational effects (2) 341
	 PPARG	modification	leading	to	adipogenesis 72
 Thermal stress leading to population decline (3) 326
Reactive oxygen Chronic ROS leading to human treatment-resistant gastric cancer 298
species,  Frustrated phagocytosis-induced lung cancer 303
ROS formation,  Mitochondrial complex inhibition leading to liver injury 273
ROS generation
 Cholestatic liver injury induced by inhibition of the bile salt export pump (ABCB11) 27
 Inhibition of fatty acid beta oxidation leading to nonalcoholic steatohepatitis (NASH) 213
 Unknown MIE renal failure 186
 Calcium-mediated neuronal ROS production and energy imbalance 26
 Excessive ROS leading to mortality  327
 Excessive ROS leading to mortality  328
 Excessive ROS leading to mortality  329
 Excessive ROS leading to mortality  330
 Uncoupling of OXPHOS leading to growth inhibition  266
 Uncoupling of OXPHOS leading to growth inhibition  267
 Uncoupling of OXPHOS leading to growth inhibition  268
 ROS production leading to population decline via mitochondrial dysfunction 311
 ROS production leading to population decline via follicular atresia 216
 Thermal stress leading to population decline  325
 Thermal stress leading to population decline  326
 NADPH oxidase activation leading to reproductive failure 207
 Reactive oxygen species generated from photoreactive chemicals leading to 282 
 phototoxic reactions
 ROS production leading to population decline via reduced FAO 299
 ROS production leading to population decline via LPO 238
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3.3.2  Case study 2: Liver fibrosis
The liver is known to be one of the main target organs for ingest-
ed NMs. Therefore, we explored the AOPs for liver fibrosis pre-
sented in AOP-Wiki to generate in vitro test strategies for NMs.
The schemes shown in Figure 5 both lead to liver fibrosis as 
follows: 
– AOP 144 with MIE endocytic lysosomal uptake: Endocyt-
ic lysosomal uptake (MIE) of the stressor leads to lysosom-
al disruption (KE1), which induces subsequent KEs at the 
cellular level such as mitochondrial dysfunction (KE2), cell 
injury and apoptosis/necrosis (KE3). Cell death leads to in-
creased production of pro-inflammatory mediators (KE4), 
which attract and activate leukocytes (KE5). Activated leu-
kocytes through molecular mediators activate hepatic stel-
late cells (HSCs) (KE6), which increase the accumulation of 
collagen (KE7) leading to extracellular matrix (ECM) alter-
ation and AO – liver fibrosis. 
– AOP 38 with protein alkylation: presented with similar 
downstream KEs as in AOP 144 (KE3, KE6 and KE7) ex-
cept that liver tissue resident macrophages release media-
EMT transition can be measured by quantifying mesenchymal 
cell markers such as vimentin and β-catenin. These polarized epi-
thelial cells are involved in the production of collagen (measured 
by collagen assay). 
TS2: IL-1β promotes the secretion of TGF-β1, which plays a 
key role in fibroblast activation and proliferation. Activated fi-
broblasts (KE3) are involved in the production of collagen. IL-18 
is also involved in the direct activation of fibroblasts. Collagen 
production in exposed epithelial cells (TS1) and lung fibroblasts 
(TS2) can be measured as a representative in vitro AO to predict 
lung fibrosis in vivo.
TS3: Macrophages, the first line of defense that engulfs NMs 
by phagocytosis, also play a key role in the development of lung 
fibrosis. Upon inflammasome activation due to frustrated phago-
cytosis (characterized by TEM), macrophages secrete IL-1β and 
TNF-α, which are involved in promoting TGF-β1, which in turn 
activates fibroblasts (KE3) and promotes collagen production. 
From the obtained results, the potency of a NM to trigger a 
MIE leading to AO (collagen production) via any of these path-
ways (TS1, 2 and 3) can be determined.   
Fig. 3: Schematic representation of AOP 173
Fig. 4: Proposed in vitro strategy to test the potential of a NM to induce lung fibrosis
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sured by assays such as neutral red/acridine orange) and KE1 
mitochondrial dysfunction (mitochondrial membrane potential, 
MMP) of hepatocytes lead to KE2 cell injury (cytotoxicity as-
says such as WST-1, LDH). Release of damage-associated mo-
lecular pattern (DAMP) mediators and cytokines such as TNF-α 
and TGF-β are involved in the direct activation of HSCs (KE3), 
a major source of collagen producing cells (AO) in the liver (Liu 
et al., 2012; Li et al., 2008). HSCs also become activated upon 
engulfment of DNA fragments from apoptotic hepatocytes (Li et 
al., 2008). To verify this, HSCs can be incubated with cell culture 
tors, which activate HSC (instead of mediators released by 
leukocytes) and with protein alkylation as MIE (Fig. 5).
In the literature, it has been reported that several NMs induce ly-
sosomal disruption and apoptosis/necrosis via lysosomal mem-
brane permeabilization (LMP) (Stern et al., 2012). Therefore, we 
propose three test strategies using simple in vitro experiments 
with LMP as an initial KE (Fig. 6).
TS1: Hepatocytes (epithelial cells) can be used as a cell model 
as ingested NMs, once entering the liver via the portal vein, en-
counter the epithelial layer of the liver. NM-induced LMP (mea-
Fig. 5: Schematic representation of liver fibrosis AOPs as presented in AOP-Wiki
Fig. 6: Proposed in vitro strategy to test the potential of a NM to induce liver fibrosis
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reported in nanotoxicological studies, their relevance in terms of 
predicting the AO is unknown. AOPs are relevant in the context 
of organizing the existing information to establish relationships 
between key biological endpoints for AO prediction. Although 
more than 200 AOPs are currently available in the AOP-Wiki, it 
is important to note that only a handful of AOPs have been for-
mally validated or endorsed by the OECD. Furthermore, in vitro 
exposure models and assays that are currently being used to mea-
sure KEs need to be validated for testing of NMs. Until reach-
ing the stage of availability of validated in vitro assays and ex-
posure models as well as AOPs for NMs, our strategy based on 
existing AOPs is useful in the following contexts: (i) addressing 
the knowledge gaps in AOPs, (ii) early screening of NM safe-
ty assessment to prioritize animal research, and (iii) determin-
ing the influence of NM property, NM concentration, and dura-
tion of exposure in observing AO. In order to test the strategies 
proposed for lung and liver fibrosis, it could be worth focusing 
on MWCNTs because the countless number of variants differ in 
length, diameter, rigidness, functional groups and impurities, and 
because the data already points to effects on lung fibrosis in vivo 
for some of them (Porter et al., 2010; Mercer et al., 2011; Duke 
and Bonner, 2018).
Very recently, based on in vitro and in vivo studies, AOPs 
related to the carcinogenicity of TiO2 NMs (Braakhuis et al., 
2021) and AOPs related to steatosis, edema and fibrosis in the 
liver induced upon TiO2 exposure (Brand et al., 2020; Gerloff et 
al., 2017) have been postulated. When analyzing these AOPs, 
we found that lysosomal injury or lysosomal membrane perme-
abilization, ROS formation, and DNA damage have been de-
scribed as early KEs. These initiating KEs have also been iden-
tified in our study, indicating their potential usefulness in the 
characterization of NM-related MIEs. Particularly with the ap-
plication of high-throughput screening and high-content as-
says, a large amount of NMs can be screened for their poten-
tially hazardous nature. Application of nano-specific AOPs for 
human health risk assessment cannot be efficient without un-
derstanding the in vitro-in vivo correlation. Predictability of 
in vitro methods for in vivo AOs remains a critical issue and 
mainly concerns: a) NM dose-selection and dose-metrics, b) in 
vitro assays including cell type and assay conditions, and c) the 
nano-relevant reference materials including both negative and 
positive controls (Dobrovolskaia and McNeil, 2013). In the 
case of conventional chemicals, the OECD adopted and vali-
dated a certain number of in vitro assays against an in vivo re-
sponse. The largest knowledge gap for NMs is related to ex-
isting in vivo data that would provide validity of an in vitro as-
say to in vivo AOs. The severity of the endpoint represents an 
important factor in determining the extent of validation that 
would be required. Thus, a selection and prioritization strategy 
would involve targeting those KEs that are shared by a number 
of AOPs with the most severe health outcomes and for which 
established in vitro assays are available. For example, both case 
studies presented here share a common immunotoxic response 
medium collected from NM-exposed hepatocyte cultures, and 
collagen production in exposed HSCs can be measured as a rep-
resentative in vitro AO to predict liver fibrosis in vivo.
TS2: Leukocytes, upon activation, secrete TGF-β1 and TNF-α 
(KE3), which in turn activate HSCs (KE4) that produce colla-
gen2. Therefore, leukocytes such as monocytes can be incubat-
ed with NMs, and subsequently HSCs can be incubated with the 
medium collected from monocytes, and collagen production in 
exposed HSCs can be measured as a representative in vitro AO to 
predict liver fibrosis in vivo.
TS3: Kupffer cells, which are the liver-resident macrophages, 
also play a key role in the development of liver fibrosis. Activat-
ed Kupffer cells can secrete pro-inflammatory mediators such as 
TNF-α and IL-6 and pro-fibrotic mediator TGF-β, which leads to 
HSC activation3 (Liu et al., 2012). To verify this, Kupffer cells 
can be incubated with NMs and, subsequently, HSCs can be in-
cubated with the medium collected from Kupffer cells, and colla-
gen production in exposed HSC cells can be measured.
From the obtained results, the potency of a NM to trigger an 
initial KE leading to the AO (collagen production) via any of 
these pathways (TS1, 2 and 3) can be determined.
4  Discussion
The increasing number of applications of nanotechnology and 
the fast-growing market of nanoproducts creates an urgent need 
for the development of strategies to perform a fast and reliable 
safety testing and hazard assessment of NMs. The AOP frame-
work represents an important regulatory relevant aid in predict-
ing the adverse effects of NMs that may foster reduction/elimina-
tion of animal testing. In this paper, we describe a simple strategy 
for AOP implementation in nanotoxicology to facilitate the fast 
screening of NM safety and to provide an efficient aid to regula-
tory decision-making and the safe(r)-by-design approach to the 
development and use of NMs. 
Chemical AOPs are not stressor-specific, and we assumed 
that they could be used to postulate the downstream effects of 
NMs if proper MIEs relevant for NMs were identified. There-
fore, we systematically explored existing AOPs in AOP-Wiki 
using NM-relevant initiating KEs identified in the literature and 
proposed in vitro strategies to test the potential of a NM to in-
duce lung and liver fibrosis as two AO case studies. In addition 
to these AOPs, we realized that several AOPs identified in the 
AOP-Wiki related to liver injury (AOP 273), kidney toxicity 
(AOP 257), neurotoxicity (AOP 3), and breast cancer (AOP 293) 
can also be potentially explored for NMs. However, more infor-
mation on NM biodistribution in organs such as brain and breast 
are required to justify the use of these AOPs, which were pro-
posed for conventional chemicals. 
A recent review by Halappanavar et al. (2021) suggested that 
although cell death, membrane integrity, ROS/RNS and cyto-
kines are among the in vitro biological endpoints that are widely 
2 AOP-Wiki. Activation, stellate cells leads to accumulation, collagen, KER 295. https://aopwiki.org/relationships/295 (accessed 14.02.2021)
3 AOP-Wiki. Tissue resident cell activation, KE 1492. https://aopwiki.org/events/1492 (accessed 14.02.2021)
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assessment of KEs. Moreover, it has been well documented that 
many NM types, especially metal-based, interact with biologi-
cal structures, affecting their fate (toxicokinetics and toxicody-
namics) in biological systems (Feliu et al., 2016). 
In biological media, aggregation, agglomeration, dissolu-
tion and degradation of NMs may occur, leading to the gener-
ation and co-existence of different sizes and forms (NMs, ions 
and complex salt forms), illustrating the need for detailed ana-
lytical tools able to pick up this mixture of chemical forms and 
particle types. Some of these new species may trigger MIEs and 
KEs that are not nano-specific. Nano-bio interactions should be 
assessed and used to govern selection of in vitro tests by consid-
ering specific endpoints that derive from nano-related properties 
and transformations driven by the biological environment pres-
ent around the material. For example, lysosomal enzyme release 
and quantification of metal can be used to assess lysosomal dys-
function as a KE resulting from the active cellular uptake of me-
tallic NMs and their transformation in endosomes. 
In any case, no single in vitro model is sufficient to provide a 
comprehensive answer about safety or hazards of NMs. While 
validation of assays with regard to their relevance, reliability, and 
specificity represents the enduring need for risk governance of 
nanotechnology, we are still faced with the huge lack of human 
exposure and effects data for NMs that would foster adaptation 
and development of such methods.
The choice of exposure durations (short-term or long-term) 
and exposure concentrations is critical for the safety assessment 
of NMs as most of them exhibit very low acute toxicity (Annan-
gi et al., 2016; Xi et al., 2019; Chen et al., 2016). Indeed, most in 
vitro studies evaluated the toxic potential of NMs after short-term 
exposure (24 to 72 h), while long-term and repeated low-concen-
tration exposure studies are scarce but are extremely important 
as they better mimic real-life exposure (e.g., workers in produc-
tion and consumers through food). Since NM safety assessment 
by AOP testing is in the early stages of development, use of ex-
posure conditions and relevant in vitro models that mimic more 
closely the realistic exposure situation should be encouraged.
Considering that the regulatory relevant AOP networks extend 
and enhance the toxicity testing strategy via providing insight in-
to the mechanism of action, they also support the development of 
relevant approaches for toxicity prediction including computa-
tionally-based predictive models. Hence, linking the AOP frame-
work to in silico methods may facilitate the safety prediction of 
NMs. In silico models may be used to predict biological respons-
es of potential concern for the occurrence of the AO instead of 
predicting the apical changes measured at the phenotypic level 
(Jagiello et al., 2021). However, the relevance of the response 
used for modelling of the eventual AO first needs to be justified. 
In effect, AOP-anchored predictive models (including QSAR) 
would be delivered. The development of mathematical models 
(including QSARs) as predictive tools for early KEs is now one 
of the long-term actions according to the OECD report (OECD, 
2015). The QSAR models have been widely used for predicting 
for which the Nanotechnology Characterization Lab (NCL) has 
recommended in vitro assays with high potential for in vivo pre-
dictability (Dobrovolskaia and McNeil, 2013).
The choice of the in vitro model is the next crucial step for 
the successful application of in vitro testing strategies. The mod-
el must have the ability to exhibit crucial KEs upon exposure to 
NMs. For instance, in testing the lung fibrosis AOP, selected ep-
ithelial cells must have the ability to undergo EMT transition, 
whereas epithelial cells and macrophages must have the ability to 
release sufficient levels of pro-inflammatory and pro-fibrotic me-
diators. Agents that can induce these effects (positive agents) can 
be used to characterize the abilities of cell types to exhibit these 
KEs. As an example, TGF-β1, a strong promoter of EMT transi-
tion, can be used to check the ability of the selected cell type to 
undergo EMT transition. 
However, most validated in vitro tests are based on 2D mono-
cultures that do not reliably represent the architecture and physi-
ology of an organ and the interactions within an organism. It has 
been recommended to develop and validate test systems based on 
a combination of cell cultures, co-cultures, tissue and tissue cul-
ture models (Halappanavar et al., 2021). The AOP development 
for nanosafety assessment should benefit from advanced biolog-
ical models such as reconstructed epithelia, 3D cultures and mi-
crofluidic-based platforms that are continuously developed in the 
3Rs spirit, particularly those that allow long-term and/or low-
dose exposure to better predict chronic effects (Drasler et al., 
2017; Ruzycka et al., 2019; Barosova et al., 2020). Such mod-
els, developed to mimic human physiology and metabolism, hold 
great promise for RA of engineered NMs (Burden et al., 2021). 
As an example, advanced in vitro models of the human lung and 
liver have been used in the EU H2020 projects “Physiological-
ly Anchored Tools for Realistic nanOmateriaL hazard aSsess-
ment” (PATROLS4) and “Smart Tools for Gauging Nano Haz-
ards” (SmartNanoTox5).
Further, one should consider the reliability, reproducibili-
ty and accessibility of the in vitro testing approach for RA of 
NMs with respect to nano-specific challenges, e.g., the hetero-
geneity of NMs, the interference of NMs with assays, and the 
lack of standardized protocols (Savolainen et al., 2010; Shah 
et al., 2014). An in vitro toolbox should include selected criti-
cal checkpoints to avoid any undesirable interactions of NMs 
with assay components and/or detection systems caused by 
NM properties or high exposure concentration, which may lead 
to erroneous results (Vinković Vrček et al., 2015; Hoet et al., 
2013; Guadagnini et al., 2015; Ostermann et al., 2020; Kroll et 
al., 2011, 2012; Seiffert et al., 2012). Despite many studies ev-
idencing that nano-specific properties, such as high adsorption 
capacity, hydrophobicity, surface charge, optical and magnetic 
properties, or catalytic activity may induce interferences with 
in vitro methods, this issue has still not been adequately consid-
ered in nanotoxicology and nanomedicine. Any false positive 
and false negative results caused by NM-induced interferences 
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velopment of computationally assisted AOP development for 
NMs therefore should be based on the provision of high-quali-
ty data that support establishing full AOPs and creating predic-
tive models. 
One aspect that is generally missing in biological testing is 
the evaluation of the uncertainty in measurements (ISO, 2008), 
which would facilitate the assessment of the reliability of mea-
surements and comparison of the results obtained in different 
laboratories. We would therefore recommend the inclusion of 
measurement uncertainty as one of the important parameters for 
the overall data analysis.
Combined in vitro/in silico approaches may significantly fa-
cilitate AOP acceptance by all relevant stakeholder groups com-
ing into contact with NMs with regards to the evaluation of ex-
isting information, identification of data gaps, generation of new 
knowledge, and iterative decision making (Ede et al., 2020). Fi-
nally, the AOP framework also finds its utility in the nano-prod-
uct design and development as mechanistic aid, thereby having 
relevance beyond regulatory applications. 
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